CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 82 enrolled
Drug / intervention
Ixabepilone +2 moredrug
Likely dose
Ixabepilone 30 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00741988
NCT00741988Phase 2Completed
CompareCT.gov

Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer

SCRI Development Innovations, LLC·interventional·Posted Aug 27, 2008·Updated Dec 15, 2021

In Brief

A Phase 2 clinical trial evaluating Ixabepilone, Carboplatin, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 82 participants across 13 sites.

Detailed Summary

This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each cohort (Cohorts A and B).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Genentech, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 27, 2008
Enrollment StartSep 1, 2008
Primary CompletionSep 1, 2010
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.8 years ago

Interventions

Ixabepilonedrug

ixabepilone 30 mg/m2

Carboplatindrug

carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.

Bevacizumabdrug

bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.